Tradestie Institutional Equity Comparison Engine

LVTX vs CELU โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

LVTX Overall Edge

LVTX Captures Institutional Edge (2โ€“1 Pillars ยท 7โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to LAVA Therapeutics N.V. Ordinary Shares (LVTX) driven by superior Growth & Margin, Momentum & Technical while CELU counters with relative strength in Options & Structure. Fundamentally, LVTX trades at N/M Forward P/E with -431.9% operating margin (+1313.6% YoY revenue) versus CELU at N/M Forward P/E and -254.0% operating margin (-5.3% YoY). In options structure, LVTX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CELU sits in BREAKDOWN (50th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
LVTX N/M vs CELU N/M Fwd P/E
Growth & Margin Winner LVTX
Op Margin -431.9% vs -254.0% ยท YoY +1313.6% vs -5.3%
Momentum & Technical Winner LVTX
1Y +17.6% vs -72.6% ยท 52W Pos 77% vs 2%
Options & Structure Winner CELU
UNCLASSIFIED (N/A IV) vs BREAKDOWN (50th %ile IV)
LVTX NASDAQ
LAVA Therapeutics N.V. Ordinary Shares
Pharmaceutical Preparations
$1.74
-3.87% 1D
Market Cap $45.8M
1M Return +6.75%
1Y Return +17.57%
Forward P/E N/M
Unified AI Score
67.0 / 100 BUY
Tech 75.0 Fund 63.0 Flow 50.0 Mom 64.0
CELU NASDAQ
Celularity Inc. Class A Common Stock
Pharmaceutical Preparations
$0.46
-1.05% 1D
Market Cap $15.2M
1M Return -55.9%
1Y Return -72.6%
Forward P/E N/M
Unified AI Score
42.9 / 100 HOLD
Tech 25.0 Fund 48.0 Flow 67.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: LVTX +17.57% CELU -72.6% Spread: +5.05 pp (CELU Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
LVTX TTM Op. Margin: -431.9% CELU TTM Op. Margin: -254.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LVTX vs CELU. Trailing 12-month operating profitability (LVTX -431.9% vs CELU -254.0%) and valuation multiples (LVTX N/M vs CELU N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: LVTX (7) vs CELU (1)
Institutional Metric LVTX CELU Criterion Row Winner
Market Capitalization Scale $45.8M $15.2M Larger Scale LVTX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +1313.6% -5.3% Higher Growth LVTX
Operating Margin (TTM) Profitability -431.9% -254.0% Higher Margin CELU
Net Profit Margin Profitability 0.0% -245.7% Higher Margin LVTX
Return on Equity (ROE) Capital Efficiency -101.5% -6367.2% Higher ROE LVTX
52-Week Range Position Momentum 77% ($1โ€“$2) 2% ($0โ€“$3) Stronger Trend LVTX
Beta / 30D Volatility Risk Regime -0.02ฮฒ ยท 49% Vol 2.01ฮฒ ยท 135% Vol Lower Realized Risk LVTX
Unified Institutional Score Composite Signal 67.0 / 100 (BUY) 42.9 / 100 (HOLD) Higher Composite LVTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full LVTX vs CELU Buy Guide
LVTX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live LVTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CELU BREAKDOWN
60d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 50th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CELU Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither LVTX nor CELU registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.